Finance

Senarai
SGIOY:OTCMKTS
Shionogi 2 ADR Representing 1 Ord Shs
USD 8.70
-0.57%
(-0.050) 1H
9 Okt, 4:00:00 PTG GMT-4  ·   USD
Semua simbol
SimbolHargaPerubahan% Perubahan
Menjana cerapan popular untuk SGIOY...
Buka
USD 8.75
Tinggi
USD 8.79
Rendah
USD 8.64
Permodalan Pasaran
2.44T
Purata volum
163.32K
Volum
0.00
tgi 52 mgu
USD 12.00
rdh 52 mgu
USD 7.65
Beta
0.07
Syer tertunggak
1.78B
Bilangan pekerja
6K
Buka
USD 8.75
Tinggi
USD 8.79
Rendah
USD 8.64
Permodalan Pasaran
2.44T
Purata volum
163.32K
Volum
0.00
tgi 52 mgu
USD 12.00
rdh 52 mgu
USD 7.65
Beta
0.07
Syer tertunggak
1.78B
Bilangan pekerja
6K
Cerita berita
Daripada sumber web dan rakan kongsi berita
Profil
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana. Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines. In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan. Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV. The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index. In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
Perihal Shionogi 2 ADR Representing 1 Ord Shs
CEOIsao Teshirogi
Pekerja6.22K
Diasaskan1878
Ibu pejabat-
Sektor-
Laman webshionogi.com
Laporan sebelumnyaSemua nilai dalam JPY
Loading Previous Earnings...
Hasil
Pendapatan bersih
Semua nilai dalam JPY
Sep 2025
Dis 2025
Mac 2026
Jun 2026
Hasil
113.18B
147.72B
138.99B
163.31B
Kos barangan yang dijual
16.94B
25.09B
28.10B
30.80B
Kos hasil
16.94B
25.09B
28.10B
30.80B
Perbelanjaan penyelidikan dan pembangunan
27.55B
29.87B
40.54B
31.79B
Jumlah perbelanjaan penyelidikan dan pembangunan
-
-
-
-
Perbelanjaan jualan, am dan pentadbiran
27.56B
35.27B
32.92B
44.36B
Belanja kendalian
56.57B
48.45B
100.06B
113.87B
Jumlah belanja kendalian
73.51B
73.54B
128.17B
144.66B
Pendapatan kendalian
39.67B
74.18B
10.83B
18.64B
Pendapatan bukan kendalian lain
-
-1.00J
7.31B
-2.00J
EBT termasuk item luar biasa
52.06B
92.89B
47.64B
73.74B
EBT tidak termasuk item luar biasa
52.06B
93.10B
47.80B
25.47B
Belanja cukai pendapatan
7.87B
18.21B
-56.00J
-23.98B
Kadar cukai berkesan
15.12%
19.60%
-0.12%
-32.52%
Belanja kendalian lain
979.00J
-17.25B
15.44B
21.90B
Pendapatan bersih
44.19B
74.68B
46.93B
97.70B
Margin untung bersih
39.04%
50.56%
33.77%
59.82%
Perolehan bagi setiap syer
-
-
-
-
Pendapatan faedah dan pelaburan
14.21B
20.53B
23.73B
12.15B
Belanja faedah
-1.82B
-1.61B
-
-5.32B
Belanja faedah bersih
12.38B
18.92B
23.73B
6.82B
Caj susut nilai dan pelunasan
-485.00J
-
-1.53B
-
EBITDA
44.83B
80.21B
21.59B
39.52B
Keuntungan atau kerugian daripada jualan aset
-
-
35.04B
-
Kandungan AI boleh mengandungi kesilapan. Ketahui lebih lanjut
BantuanHantar maklum balasPrivasiSyaratPenafian
Apl Google